274263-96-6

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 31827-94-8 2-bromo-1-(4-iodophenyl)ethanone 

Downstream Products

• 274263-98-8 6-methyl-2-(4'-iodophenyl)-3-dimethylaminomethylimidazo[1,2-a]pyridine 
• 1228303-18-1 [2-(4-iodophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]methanol 
• 274264-04-9 6-methyl-2-(4'-iodophenyl)imidazo[1,2-a]pyridine-3-acetic acid 
• 274264-02-7 6-methyl-2-(4'-iodophenyl)imidazo[1,2-a]pyridine-3-acetonitrile 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE COMPOUNDS

The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

Synthesis of [123I]N',N'-dimethyl-6-methyl-(4'-iodophenyl)imidazo[1,2-a]pyridine-3-acetamide for the study of peripheral benzodiazepine receptors using SPECT

The [123I] labelled imidazo[1,2-a]pyridine [123I]iodozolpidem 4 was found to exhibit preferential activity towards Peripheral rather than Central Benzodiazepine receptors in vivo and was synthesised for the potential study of the Peripheral Benzodiazepine Receptors (PBR) using SPECT. [123I]Iodozolpidem was prepared from the corresponding tributyl tin precursor by iododestannylation with Na[123I] in the presence of peracetic acid or chloramine-T. Purification by semipreparative C-18 RP HPLC gave the product in radiochemical yields of 60-85%. The product was obtained in > 97% chemical and radiochemical puritiy with a specific activity > 80 GBq/μmol.